Literature DB >> 11264257

The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury.

R Suzuki1, L C Stanfa, E A Kowaluk, M Williams, M F Jarvis, A H Dickenson.   

Abstract

1. Adenosine (ADO) receptor activation modulates sensory transmission in the dorsal horn. Little is known about the circumstances underlying release of the purine. The present study was conducted to investigate the effect of a novel and potent non-nucleoside adenosine kinase (AK) inhibitor, ABT-702, on the responses of dorsal horn neurones to selected peripheral stimuli. ABT-702 is orally effective to reduce behavioural signs of nociception in models of acute, inflammatory, and neuropathic pain. 2. Electrophysiological recordings were made from wide dynamic range (WDR) neurones in halothane-anaesthetized rats. ABT-702 was given subcutaneously following either carrageenan inflammation or peripheral nerve injury (L5/L6 spinal nerve ligation). Comparisons were made between carrageenan and uninjected control animals, and similarly between spinal nerve ligated (SNL) and sham operated animals. 3. ABT-702 produced inhibition of the postdischarge, wind-up and C-fibre evoked responses in both carrageenan and nerve-injured animals. Furthermore, the mechanical and thermal evoked responses were similarly reduced in SNL rats. Overall, ABT-702 produced a significantly greater inhibition of these responses in SNL rats as compared to sham controls. Similarly ABT-702 tended to produce greater effects after carrageenan inflammation, however this did not reach significance. 4. Protection of endogenous adenosine by ABT-702 therefore produces a marked inhibition of the noxious evoked neuronal activity in inflamed and neuropathic rats. Our results demonstrate a plasticity in the endogenous adenosine-mediated inhibitory system following SNL and provide a possible basis for the use of this compound for the treatment of neuropathic and other persistent pain states.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264257      PMCID: PMC1572706          DOI: 10.1038/sj.bjp.0703972

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Activities and some properties of 5'-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine.

Authors:  J R Arch; E A Newsholme
Journal:  Biochem J       Date:  1978-09-15       Impact factor: 3.857

2.  Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy.

Authors:  R Suzuki; E A Matthews; A H Dickenson
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

3.  Intrathecal adenosine does not relieve allodynia-like behavior in spinally injured rats.

Authors:  M von Heijne; J X Hao; A Sollevi; X J Xu
Journal:  Neuroreport       Date:  1999-10-19       Impact factor: 1.837

4.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

5.  Classification of adenosine receptors mediating antinociception in the rat spinal cord.

Authors:  J Sawynok; M I Sweeney; T D White
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

6.  ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.

Authors:  E A Kowaluk; J Mikusa; C T Wismer; C Z Zhu; E Schweitzer; J J Lynch; C H Lee; M Jiang; S S Bhagwat; A Gomtsyan; J McKie; B F Cox; J Polakowski; G Reinhart; M Williams; M F Jarvis
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

7.  ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.

Authors:  M F Jarvis; H Yu; K Kohlhaas; K Alexander; C H Lee; M Jiang; S S Bhagwat; M Williams; E A Kowaluk
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

8.  Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain.

Authors:  Alf Sollevi; Måns Belfrage; Thomas Lundeberg; Märta Segerdahl; Per Hansson
Journal:  Pain       Date:  1995-04       Impact factor: 6.961

9.  Adenosine kinase and adenosine deaminase inhibition modulate spinal adenosine- and opioid agonist-induced antinociception in mice.

Authors:  G J Keil; G E DeLander
Journal:  Eur J Pharmacol       Date:  1994-12-12       Impact factor: 4.432

10.  Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain.

Authors:  M Belfrage; A Sollevi; M Segerdahl; K F Sjölund; P Hansson
Journal:  Anesth Analg       Date:  1995-10       Impact factor: 5.108

View more
  9 in total

1.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

2.  Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss.

Authors:  Srdjan M Vlajkovic; Cindy X Guo; Ravindra Telang; Ann Chi Yan Wong; Vinthiya Paramananthasivam; Detlev Boison; Gary D Housley; Peter R Thorne
Journal:  Exp Gerontol       Date:  2011-08-07       Impact factor: 4.032

Review 3.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 4.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

Review 5.  Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.

Authors:  Detlev Boison; Kerry-Ann Stewart
Journal:  Biochem Pharmacol       Date:  2009-08-12       Impact factor: 5.858

6.  Role of adenosine kinase in cochlear development and response to noise.

Authors:  Srdjan M Vlajkovic; Cindy X Guo; Nuwan Dharmawardana; Ann Chi Yan Wong; Detlev Boison; Gary D Housley; Peter R Thorne
Journal:  J Neurosci Res       Date:  2010-09       Impact factor: 4.164

7.  Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat.

Authors:  Curtis O Asante; Victoria C Wallace; Anthony H Dickenson
Journal:  J Pain       Date:  2010-05-08       Impact factor: 5.820

8.  Interleukin-1 receptor type 1 is overexpressed in neurons but not in glial cells within the rat superficial spinal dorsal horn in complete Freund adjuvant-induced inflammatory pain.

Authors:  Krisztina Holló; László Ducza; Zoltán Hegyi; Klaudia Dócs; Krisztina Hegedűs; Erzsébet Bakk; Ildikó Papp; Gréta Kis; Zoltán Mészár; Zsuzsanna Bardóczi; Miklós Antal
Journal:  J Neuroinflammation       Date:  2017-06-23       Impact factor: 8.322

Review 9.  Purinergic Signaling in Endometriosis-Associated Pain.

Authors:  Carla Trapero; Mireia Martín-Satué
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.